Managing cancer can be difficult for both patients and families. Many patients rely on long term medication for treatment and assistance with managing everyday life. Innovative caner treatment solutions provider Seattle Genetics is conducting an advanced clinical trial for their new cancer treatment ADCETRIS. Company CEO Clay Siegall anticipates the trial will have the most significant impact on Seattle Genetics. ADCETRIS will be used to treat patients who are battling Hodgkin lymphoma. Patients in the United States and Canada spent nearly $250 million on the drug in 2015. Currently, Seattle Genetics offers 13 different cancer treatment options, including ADCETRIS.
Seattle Genetics’ ambitious plan for 12 more drugs, 100 more employees
Seattle Genetics is a biotechnology company that focuses on providing antibody-based cancer treatment therapy options. They are considered world leaders in cancer treatment and delivering innovative and less invasive treatment options to patients and their families. Seattle Genetics focuses heavily on antibody-drug conjugates (ADCs) in efforts to develop treatments that will directly attack cancer cells. The use of these type of drugs also reduces the risk of experiencing harmful side effects that chemotherapy may produce.
Seattle Genetics was founded and incorporated on 1997 thanks to Clay Siegall, and his since collaborated with Takeda Oncology Company to help promote ADCETRIS and make it available to the public. Currently, they are working on a new ACD based treatment that will rely on a pyrrolobenzodiazepine dimer or PBD, to completely kill the cancerous cells. With their team of over 650 dedicated and experienced professionals working tirelessly to promote healthier cancer treatment options, Seattle Genetics is headed to the top of the list in worlds most innovative cancer treatment providers.